---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-113055"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-10-02T12:18:25+00:00"
generated_at: "2026-10-12T14:31:53.397353+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics reports CNTY-813 nonclinical data at EASD; IND filing on track for Q4 2026

## Summary
- CNTY-813 maintained glycemic control in diabetic mice over an 11-month study until graft removal; all streptozotocin-induced diabetic mice dosed with CNTY-813 achieved normoglycemia.
- Five clinical-scale GMP batches produced consistent product via a 29-day process that exceeded purity criteria at every stage.
- Clinical-scale islets stored 96 hours cold normalized blood glucose in mice within 30 days and held normoglycemia through three months.
- Rat liver portal vein delivery yielded engraftment at one month, with islets staining positive for chromogranin A and insulin.
- CEO Brent Pfeiffenberger said the CNTY-813 IND submission remains on track for Q4 2026, with initial clinical data anticipated in 2H 2027.

## SEC filing metadata
- accession: 0001104659-26-113055
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-10-02T12:18:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926113055/0001104659-26-113055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926113055/tm2626840d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-113055
- JSON: https://secwatch.observer/filing/0001104659-26-113055.json
- Plain text: https://secwatch.observer/filing/0001104659-26-113055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.